UiPath beat every number and still lost a quarter of its value. The selloff is pricing growth, not disappointment

A company reports a beat, raises its full-year outlook, and the stock falls roughly 25% in three trading days. That sort of chart normally produces one of two reactions: panic, or the smug contrarian who smells an overdone selloff. UiPath's case deserves a third look before either instinct takes over, because the market is not reacting to the quarter at all. It is reacting to what the quarter says about how fast this company grows next.

The paradox: a clean quarter, an $18 stock now selling for $14

For the three months ended July 31, UiPath reported $410 million in revenue, up 13% from a year earlier and ahead of the roughly $398 million analysts expected. Adjusted operating income came in at $89 million, above the company's own guidance of $75 million. Management raised revenue guidance for the full fiscal year. By the numbers, this was the rare report with few genuine complaints — and the stock still sank 17% the next day and another 8% by Tuesday, to about $14.

The trigger was the part of the release that does not get emphasized in a headline: guidance for the coming quarter. UiPath guided fiscal third-quarter revenue to $440–445 million, a range whose midpoint implies year-over-year growth of only about 8%. Three months earlier that growth rate was 13%. A software company whose forward growth rate just got cut almost in half in one quarter is not a company whose multiple should stay where it was — so the market cut the multiple.

This is the mechanical heart of a "growth scare": nothing in the just-reported quarter was wrong, but the trajectory the guidance revealed was worse than the price had been built to tolerate. And that matters more because of how the stock arrived at its pre-earnings price. UiPath had already rallied about 30% in the three months before the report, lifting the stock from the mid-teens range near its 52-week low of roughly $9 into the high $18s, on optimism that its pivot toward agentic-AI orchestration was working. A valuation that stretches in the good news rarely survives disappointing news about the future, even when the reported quarter is fine.

The one number that separates panic from real damage

The natural contrarian question is whether this is selling exhaustion or genuine deterioration. On that, the balance of evidence is more uncomfortable for the contrarian than the surface story suggests.

UiPath's core subscription number is its annualized recurring revenue, or ARR. It reached $1.94 billion, up 12%. The subtler figure is net new ARR — the fresh recurring revenue added in the quarter — which fell to $37 million from $49 million in the prior quarter. That is a 24% quarter-over-quarter slowdown in the single metric that most directly measures whether the business is pulling in new customers faster or slower. Alongside it, dollar-based net retention held at 109%, meaning existing customers are still spending more, but the engine of new demand is cooling.

That cooling is exactly where the market's worry about agentic AI shows up. UiPath's classic product automates repetitive, deterministic tasks — the familiar "robotic process automation" robots. The fear is that AI agents, which can decide and adapt as they work, are taking over part of that job and slowing enterprise buying of "bots" faster than UiPath can repackage itself as the orchestration layer that governs those agents. The company's own chief executive frames AI as expanding the need for the governance and exactness that deterministic automation provides. That is a coherent pitch. But a coherent pitch is not the same as a proven moat, and the falling net-new-ARR number is real evidence that customers are taking longer to commit. Competition exists and the moat is breached are different claims — and the honest reading here is that a slowing pipeline is a data point pointing toward the former being tested.

What the price is paying for now

So the central question becomes less "is the market crazy?" and more "how far is further deceleration already baked in?" At $14, UiPath trades at an enterprise value of roughly $6 billion. Against the roughly $1.79 billion of revenue guided for this fiscal year, that is a little over three times sales — a substantial re-rating down from where the stock traded a week ago. The company holds about $1.4 billion in cash and marketable securities against essentially no net debt, and it generated roughly $363 million in free cash flow over the trailing twelve months, a figure up over 17% year over year. That works out to a free-cash-flow yield near 5% on a profitable, net-cash business that is still growing double digits — a profile that is not obviously expensive, if growth stabilizes.

That "if" is the entire debate. AInvest's aggregate rating signal labels UiPath a Hold, and the street's own mean price target sits only modestly above the current share price — even where sell-side opinion exists, it is not calling a dramatic recovery.

The discipline problem for a beginner eyeing this as a beaten-down bargain is that this is not the clean "market overreacting to a miss" setup. There was no miss, and the market still sold — because the market understood the guide to mean the growth rate is falling, and the ARR data supports that fear rather than contradicting it. Buying here is betting that the market has overshot the slowdown, not that it invented one. That can be a fine long-horizon thesis for a profitable company with a fortress balance sheet and a defensible orchestration story, but it is a bet that hinges on the near-term numbers stabilizing first.

The one figure that resolves it is the one that just turned down: net new ARR. If the next quarter or two shows that $37 million figure inflecting back up — or even holding — the growth scare loses its factual footing and the current price starts to look like it has done the bears' work for them. If it keeps sliding, the market's 25% haircut starts to look prescient rather than excessive. Until one of those is visible, UiPath is a real moat-under-stress test, not an automatic buy-the-dip. Investors who believe the deceleration is temporary have a case worth holding; those who want confirmation should let the number do the talking before the knife stops falling.